Report of Foreign Issuer (6-k)
September 09 2019 - 8:01AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
Form
6-K
Report
of Foreign Private Issuer
Pursuant
to Rule 13a-16 or 15d-16
under
the Securities Exchange Act of 1934
For
the month of: September 2019
Commission
file number: 001-36578
ENLIVEX
THERAPEUTICS LTD.
(Translation
of registrant’s name into English)
14
Einstein Street, Nes Ziona, Israel 7403618
(Address
of principal executive offices)
Indicate
by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form
20-F ☒ Form 40-F ☐
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(1): ☐
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(7): ☐
As
previously announced, Enlivex Therapeutics Ltd., a company organized under the laws of the State of Israel (the “Company”),
will deliver a corporate presentation at the 21st Annual Global Investment Conference, sponsored by H.C. Wainwright & Co.,
being held at the Lotte New York Palace Hotel in New York. The presentation is scheduled for September 9th 2019 at 2:10pm New
York time, during which the Company will present certain slides (the “Presentation”). A copy of the Presentation
is furnished hereto as Exhibit 99.1 to this Report on Form 6-K and incorporated by reference herein.
Exhibit
No.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
|
|
Enlivex
Therapeutics Ltd.
|
|
|
(Registrant)
|
|
|
|
|
|
By:
|
/s/
Shai Novik
|
|
|
Name:
Title:
|
Shai
Novik
Executive Chairman
|
Date:
September 9, 2019
2
Enlivex Therapeutics (NASDAQ:ENLV)
Historical Stock Chart
From Mar 2024 to Apr 2024
Enlivex Therapeutics (NASDAQ:ENLV)
Historical Stock Chart
From Apr 2023 to Apr 2024
